News & Videos - HOLOGIC INC.

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended July 1, 2023 . “Hologic again delivered solid, diversified growth in our fiscal third quarter, excluding the impact of COVID,” said Steve MacMillan, the Company’s chairman, president and chief executive officer. “Our results once again highlight that Hologic’s transformation and post-pandemic performance is durable. Our business is operating from a position of strength,...

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2023 on Monday, July 31, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (877) 400-0505 (in the United States and Canada) or +1 (773) 305-6865 (for international callers) and referencing access code 3332917. Participants may...

Hologic Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Panther Fusion® SARS-CoV-2/Flu A/B/RSV assay. This assay is a molecular diagnostic test that detects and differentiates four of the most prevalent respiratory viruses that can exhibit similar clinical symptoms: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A (flu A), influenza B (flu B) and respiratory syncytial virus (RSV). This...

Hologic Announces Partnership with NFL Rookie Kelee Ringo and Family PR Newswire MARLBOROUGH, Mass., May 16, 2023 MARLBOROUGH, Mass. , May 16, 2023 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced a new partnership with recently drafted NFL cornerback Kelee Ringo and his mother, breast cancer survivor Tralee Hale , to educate women on the importance of prioritizing annual mammograms and other key health screenings. Ringo is a two-time national champion...

Hologic Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced a partnership with recently drafted NFL cornerback Kelee Ringo and his mother, breast cancer survivor Tralee Hale, to educate women on the importance of prioritizing annual mammograms and other key health screenings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230508005184/en/ NFL cornerback Kelee Ringo and his mother, breast cancer survivor Tralee...

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the BofA Securities 2023 Healthcare Conference in Las Vegas, NV on Tuesday, May 9 at 2:20 p.m. Pacific Time. The presentation will be webcast live and may be accessed through a link on the investors section of Hologic’s website at http://investors.hologic.com . The webcast will be available for 30 days following the event. About Hologic Hologic, Inc. is an innovative medical technology company primarily focused on...

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended April 1, 2023 . “Hologic posted robust financial results in our second fiscal quarter, with both revenue and earnings exceeding our prior guidance,” said Steve MacMillan, the Company’s chairman, president and chief executive officer. “Each of our core franchises grew double digits in the period, with consolidated organic growth of more than 20%, excluding the impact of...

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2023 on Monday, May 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (888) 600-4862 (in the United States and Canada) or +1 (773) 305-6865 (for international callers) and referencing access code 2312014. Participants may...

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Cowen 43 rd Annual Health Care Conference on Tuesday, March 7 at 9:10 a.m. Eastern Time (E.T.) Cowen’s 43 rd Annual Health Care Conference is taking place March 6 - 8, 2023, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative panel discussions hosted by members of the Cowen research team that focus on various aspects of the health care...

Hologic, Inc. (Nasdaq: HOLX) announced today the publishing of “Making a World of Difference,” its latest annual report detailing the company’s sustainability strategy and achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230221005648/en/ Hologic 2022 Sustainability Report (Graphic: Business Wire) The report highlights how Hologic’s purpose – to enable healthier lives everywhere, every day – drives a commitment...

BD Onclarity™ HPV Assay Receives FDA Approval for Use with Both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test PR Newswire FRANKLIN LAKES, N.J., Feb. 21, 2023 Expands Access to BD HPV Test that More Precisely Identifies Patients' Risk for Cervical Cancer FRANKLIN LAKES, N.J. , Feb. 21, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) market approval for...

Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Court of Appeals for the Federal Circuit unanimously affirmed a 2021 district court ruling that invalidated a Minerva patent asserted against Hologic. The appellate court ruled that Minerva’s patent is invalid because it waited more than a year to file a patent application after showing a prototype of the invention at a trade show. “We are pleased with the U.S. Court of Appeals decision to invalidate Minerva’s patent. It confirms...

Hologic Inc. (Nasdaq: HOLX), a global leader in women's health, has announced approval of the NovaSure ® V5 global endometrial ablation (GEA) device in Canada and Europe. This innovative new version incorporates enhanced features designed to treat a wide range of cervical and uterine anatomies. It builds on a world-class track record for NovaSure, including 3 million patients who have benefited from the device. This press release features multimedia. View the full release here:...

Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal first quarter ended December 31, 2022 . “In our first quarter of fiscal 2023, each of our base franchises exceeded revenue expectations, while also delivering robust profitability,” said Steve MacMillan, the Company’s chairman, president and chief executive officer. “We had a strong start to our fiscal year with double-digit organic revenue growth ex. COVID-19 in our Diagnostics and Surgical...

Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 31, 2022. The Company expects to report total revenues of approximately $1,074.2 million, a decrease of (27.0%) compared to the prior year period, or (25.1%) in constant currency. These preliminary results are higher than the Company’s most recent revenue guidance range of $940 to $990 million, which was provided on October 31, 2022. “We delivered robust revenue performance in...

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2023 on Wednesday, February 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (877) 502-9276 (in the United States and Canada) or +1 (773)-305-6867 (for international callers) and referencing access code 3278967....

Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. Pacific Time. The presentation and Q&A session will be webcast live and may be accessed through a link on the Investors section of Hologic’s website at http://investors.hologic.com . The webcast will be available for 30 days following the event. About Hologic, Inc. Hologic, Inc. is an innovative medical technology company...

Hologic, Inc. (Nasdaq: HOLX) announced today that Stacey D. Stewart has been elected to the Company’s Board of Directors, effective January 2, 2023. Ms. Stewart was also appointed to the Audit and Finance Committee effective January 2, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221209005067/en/ Stacey D. Stewart (Photo: Business Wire) Ms. Stewart has served as President and CEO of March of Dimes Inc., a leading non-profit...

Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced new study data showing that the Breast Cancer Index test identified which premenopausal patients with early-stage, hormone-receptor positive (HR+) breast cancer benefited from the addition of ovarian function suppression (OFS) to primary adjuvant endocrine therapy. The Breast Cancer Index test is the first biomarker to be evaluated in a cohort from the landmark Suppression of Ovarian Function Trial (SOFT)....

Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health, swept the 2022 IMV ServiceTrak™ Awards for Mammography, taking home awards for Best Service, Best Customer Satisfaction and Best System Performance. This is the 10 th consecutive year that Hologic has ranked first in the industry for Mammography System Performance and Customer Satisfaction and the eighth year for Mammography Service. “We are thrilled to win the IMV Award...